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Introduction
Serum tumor makers have been used in clinical manage-
ment for diverse cancers. These markers can be used in 
screening early malignancy, diagnosis, determining prog-
nosis, monitoring response to therapy, and postoperative 
surveillance [1, 2]. For sarcomas, alkaline phosphatase 
(ALP) and lactate dehydrogenase (LDH) in osteosarcoma 
[3–5], LDH in Ewing`s sarcoma [6, 7], and myoglobin 
in rhabdomyosarcoma [8] have been identified and reported 
as prognostic serum markers. However, the role of these 
serum markers as tumor markers for sarcoma has not 
been established.
ALP is a ubiquitous enzyme present in all tissues but 
is mainly concentrated in the liver, kidney, placenta, and 
bone [9]. In the musculoskeletal system, ALP is abundant 
in osteoblasts and is considered to play a role in the 
mineralization of newly formed bone. Serum ALP is con-
sidered a bone- forming marker [10, 11]. and has been 
used to monitor primary bone lesions. In fact, elevated 
levels of ALP in severe primary bone lesions have been 
reported [3, 4, 12, 13], and the possible role of ALP as 
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Abstract
The goal of this study was to reassess serum alkaline phosphatase (ALP) as 
tumor marker in osteosarcoma. We retrospectively examined serum ALP levels 
at diagnosis, every therapeutic step (neoadjuvant chemotherapy, surgery, and 
adjuvant chemotherapy), metastasis, and follow- up and analyzed the role of 
ALP as tumor marker in 210 osteosarcomas. The diagnostic performances of 
ALP were validated with pathology- proven 899 other primary bone lesions. 
Elevated ALP at diagnosis was associated with inferior overall survival (OS) 
(Log Rank P < 0.001) and disease- free survival (Log Rank P = 0.005) and 
independently significant for OS in multivariate analysis (hazard ratio [HR]=2.12, 
P = 0.032). During therapy, the ALP level significantly changed according to 
therapeutic steps (P < 0.001 for patients ≥15 years old, P < 0.001 for patients 
<15 years old) and survival (P = 0.015 for ≥15 years, P = 0.002 for <15 years), 
and the response of ALP to therapy and survival were associated (P = 0.042 
for ≥15 years, P = 0.036 for <15 years). Initial ALP level was linearly correlated 
with tumor burden (total tumor volume; P = 0.016 for ≥15 years, bone tumor 
volume; P = 0.012 for ≥15 years). The sensitivity and specificity of ALP on 
diagnosis were 53.2% (95% Confidence Interval [CI]: 0.475–0.586) and 90.1% 
(95% CI: 0.888–0.913). The sensitivity of ALP on metastasis was 53.2% (95% 
CI: 0.431–0.624), and the specificity was 78.2% (95% CI: 0.720–0.839) 
at15 months postoperative and 90.0% (95% CI: 0.824–0.952) at 3 years post-
operative. Serum ALP was found to be a valuable tumor marker with high 
specificity in osteosarcoma.
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tumor marker in osteosarcoma has been suggested [5, 
14]. However, clinical values of elevated levels of ALP in 
those diseases have not been validated.
To be an ideal tumor marker, a serum marker should 
meet several clinical requirements:[15] The marker should 
be sufficiently sensitive and specific to the tumor, directly 
reflect tumor burden, correlate with results of therapy, 
and be useful for postoperative surveillance. For integra-
tion of a tumor marker into clinical practice, the charac-
teristics of the marker must be validated to determine 
whether they meet these clinical requirements. We examined 
serum levels of ALP at every therapeutic step and during 
follow- up from diagnosis to the last postoperative surveil-
lance, analyzed them with respect to other clinical factors, 
and reassessed ALP as a tumor marker for osteosarcoma 
usingcriteria for the clinical requirements listed above.
Materials and Methods
Patients
We retrospectively reviewed the medical records of 210 
patients who had been treated for osteosarcoma between 
October 1988 and November 2013 in Severance Hospital 
(Seoul, Korea). We examined the levels of serum ALP at 
diagnosis, every therapeutic step (neoadjuvant chemo-
therapy, surgery, and adjuvant chemotherapy), metastasis, 
and every follow- up and analyzed them according to 
oncologic outcomes and other clinical factors. To validate 
the diagnostic performance of ALP, we also reviewed the 
ALP level at presentation for 899 patients with other 
primary bone lesions, including 208 with malignant bone 
tumors, 565 with benign bone tumors, and 126 with 
osteomyelitis, all of which were pathologically confirmed 
between January 1987 and January 2014 at Severance 
Hospital. This study protocol was approved by Severance 
Hospital institutional review board. The clinical charac-
teristics of the enrolled 210 osteosarcoma patients are 
listed in Table 1. Among the total study population, 197 
(93.5%) patients received surgery and 13 (6.2%) patients 
were inoperable, and 186 (88.6%) patients received chemo-
therapy and 24 (11.4%) patients did not. Among these 
186 patients, 169 patients received both neoadjuvant and 
adjuvant chemotherapy, four received only adjuvant chem-
otherapy, and 13 received palliative chemotherapy without 
surgery. Among the 169 patients, 81 (47.9%) patients were 
treated with a doublet regimen of intraarterial cisplatin 
and doxorubicin; 76 (45.0%) were treated with a triplet 
of intraarterial cisplatin, doxorubicin, and ifosfamide; and 
12 (7.1%) were treated with other regimens. Histologic 
and oncologic outcomes of neoadjuvant chemotherapy 
were not significantly different between doublet and triplet 
regimens in our cohort [16].
Methods of serum ALP assays
Serum ALP levels were quantified in international units 
(IU), and enzyme activity was measured by the 
p- nitrophenyl phosphate method [17]. Serum ALP levels 
in children are significantly elevated due to high skeletal 
growth velocity and rapid bone turnover rate [18]. 
Therefore, serum ALP ranges of 60.0–300.0 IU/L for patients 
aged <15 years and 38.0–115.5 IU/L for patients aged 
≥15 years were considered normal to account for age- 
related changes in serum levels. Serum ALP levels were 
estimated as total enzyme rather than bone isoenzyme.
Statistical analysis
χ2 test and Fisher`s extract test (if needed) were used to 
analyze differences in the prevalence of ALP elevation at 
diagnosis according to clinical factors. The Kaplan–Meier 
estimate was used to compare overall survival (OS) and 
disease- free survival (DFS) between groups with elevated 
and normal serum ALP level at presentation. Cox regression 
analyses were used to evaluate the prognostic ability of ALP 
elevation at presentation. Linear Mixed model (fixed model) 
was used to determine whether changes in ALP during 
treatments were associated with therapeutic steps and sur-
vival, and whether the response of serum ALP to treatments 
was associated with survival. Spearman correlation analysis 
was used to evaluate the relationship of ALP levels at pres-
entation with tumor burden. Two- way contingency table 
analysis was used to validate the diagnostic performance of 
ALP on diagnosis and metastasis. All successive data of 
serum ALP were separately analyzed in patients <15 years 
and ≥15 years because of their different reference ranges. 
All statistical analyses were performed using SPSS (version 
20.0, SPSS, Inc., Chicago, IL). All P- values were two- tailed 
and a P- value < 0.05 was considered significant.
Results
Prevalence of ALP elevation at presentation 
according to clinical factors
The overall prevalence of ALP elevation at diagnosis was 
53.2%. There were no significant differences in the preva-
lence of ALP elevation with respect to age (P = 0.395), 
tumor location (P = 0.395), Huvos grade (P = 0.158), 
resection margin (P = 0.303), pathologic fracture at pres-
entation (P = 0.156), and intracapsular extension 
(P = 0.732) in χ2 test (Table 1). However, the prevalence 
of ALP elevation at diagnosis varied significantly based 
on sex (P < 0.001), metastasis at presentation (P < 0.001), 
histologic grade (P < 0.001), size (P < 0.001), and oper-
ability (P = 0.019). When compared according to histology, 
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Table 1. Clinical characteristics and prevalence of ALP elevation at diagnosis.
Variables n (%)
ALP at diagnosis
Elevation 
n (%) Normal n (%) NA n P
Survival
5- year Survival 116 (55.2) 49 (43.0) 65 (57.0) 2 0.000
DOD 67 (31.9) 50 (78.1) 14 (21.9) 3
CDF <5 years 12 (5.7)
NED 1 (0.5)
AWD 3 (1.4)
DOC 11 (5.2)
Metastasis rate
Positive 70 (37.4) 43 (64.2) 24 (35.8) 3 0.001
Free 117 (62.6) 46 (39.3) 71 (60.7) 0
Stage
Localized 187 (89.0) 89 (47.6) 94 (50.3) 4 0.000
Metastatic 23 (11.0) 20 (90.9) 2 (9.1) 1
Age 20.5 (3–71)1
≥15 131 (62.4) 71 (55.5) 57 (44.5) 3 0.395
<15 79 (37.6) 38 (49.4) 39 (50.6) 2
Sex
Male 117 (55.7) 73 (64.0) 41 (35.0) 3 0.000
Female 93 (44.3) 36 (38.7) 55 (59.1) 2
Size
≥ 8 cm 132 (68.0) 79 (62.2) 48 (37.8) 5 0.000
< 8 cm 62 (32.0) 20 (32.3) 42 (67.7) 0
NA 16
Location
Extremity 185 (88.1) 93 (51.7) 87 (48.3) 5 0.247
Axial and proximal femur 25 (11.9) 16 (64.0) 9 (36.0) 0
Histologic grade
Low 20 (9.5) 3 (15.0) 17 (85.0) 0 0.000
High 190 (90.5) 106 (57.3) 79 (42.7) 5
Histology (High grade)
Conventional
Osteoblastic 88 (58.7) 55 (63.2) 32 (36.8) 1 0.0082
Chondroblastic 18 (12.0) 8 (44.4) 10 (55.6) 0
Fibroblastic 7 (4.7) 0 (0.0) 7 (100.0) 0
Mixed 24 (16.0) 12 (54.5) 10 (45.5) 2
Nonconventional 13 (8.7) 5 (35.8) 8 (61.5) 0
NA 42
Huvos grade
I and II 52 (32.7) 32 (64.0) 18 (36.0) 2 0.158
III and IV 107 (67.3) 54 (51.9) 50 (48.1) 3
NA 27
No chemotherapy 24
Surgery 
(Operability)
Operable 197 (93.8) 98 (51.0) 94 (49.0) 5 0.019
Inoperable 13 (6.2) 11 (84.6) 2 (15.4) 0
Resection margin
R0 182 (92.4) 89 (50.0) 89 (50.0) 4 0.303
R1 and R2 15 (7.6) 9 (64.3) 5 (35.7) 1
Pathologic fracture
Yes 12 (5.7) 4 (33.3) 8 (66.6) 0 0.156
No 198 (94.3) 105 (54.4) 88 (45.6) 5
(Continued)
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the osteoblastic type (58.7%) showed a much higher 
prevalence of elevated ALP than chondroblastic (12.0%), 
fibroblastic (4.7%), mixed (16.0%), or nonconventional 
(8.7%) types (P = 0.008). The prevalence of ALP eleva-
tion at diagnosis was also significantly associated with 
oncologic outcome; survival (P < 0.001) and metastasis 
(P = 0.001). The prevalence of ALP elevation at first 
metastasis was 53.2%, similar to that at diagnosis. There 
was no difference in the prevalence of ALP elevation at 
diagnosis between patients with elevated level of ALP at 
first metastasis and patients with normal ALP (P = 0.086).
Prognostication of ALP
The patients with elevated ALP level at presentation showed 
inferior OS (Log Rank P < 0.001) and DFS (Log Rank 
P = 0.005) compared with patients with normal ALP in 
Kaplan–Meier estimate (Fig. 1). Using Cox`s regression 
analysis, the prognostic value of ALP was compared with 
that of other prognostic factors (Table 2). The subclas-
sifications of each prognostic factor were the same as 
those shown as Table 1. Metastasis at diagnosis (P < 0.001), 
age (P = 0.021), location (P < 0.001), histologic grade 
(P = 0.038), resection margin (P < 0.001), and ALP 
(P < 0.001) were significantly associated with OS in uni-
variate analysis. ALP (P = 0.032) showed independent 
association with OS after adjusting for metastasis at diag-
nosis (P < 0.001), age (P = 0.072), location (P = 0.010), 
histologic grade (P = 0.080), and resection margin 
(P = 0.388). The statistical significance of ALP on OS 
even after adjusting for metastasis at diagnosis and his-
tologic grade was quite remarkable. Regarding DFS, loca-
tion (P = 0.001), Huvos grade (P = 0.007), resection 
margin (P = 0.001), and ALP (P = 0.006) were signifi-
cantly associated in univariated analysis. However, ALP 
(P = 0.126) was not independently associated with DFS 
and only Huvos grade (P = 0.028) was significant after 
adjusting for these factors in multivariate analysis.
Clinical characteristics of ALP with respect 
to clinical requirements of tumor marker
To validate the use of serum ALP to monitor the results 
of therapy, we analyzed changes in the ALP level through-
out treatments. Among 169 patients who had received 
neoadjuvant, surgery, and adjuvant chemotherapy, 138 
patients had good documentation of serum ALP values 
at diagnosis, after neoadjuvant therapy, after surgery, and 
after adjuvant chemotherapy. The serial measurements of 
ALP values from these 138 patients at the four therapeutic 
steps were analyzed by liner mixed modeling (Table 3). 
For patients with elevated ALP at diagnosis, of the ALP 
level varied significantly at each therapeutic step (P < 0.001 
in patients ≥15 years, P < 0.001 in patients <15 years), 
suggesting that ALP respond to neoadjuvant chemotherapy, 
surgery, and adjuvant chemotherapy. The ALP level varied 
significantly at each therapeutic step in accordance with 
the outcomes of treatment (for 5- year survival, P = 0.015 
in patients ≥15 years and P = 0.002 in patients <15 years). 
Furthermore, the ALP level also varied significantly accord-
ing to interactions between therapeutic steps and 5- years 
survival (P = 0.042 in patients ≥15 years, P = 0.036 in 
patients <15 years), suggesting that response of ALP to 
treatment and patient survival were associated (Table 3). 
However, these changes were not significant in the patients 
with normal ALP at diagnosis.
Variables n (%)
ALP at diagnosis
Elevation 
n (%) Normal n (%) NA n P
Intracapsular extension
Yes 38 (22.8) 18 (48.6) 19 (51.4) 1 0.732
No 139 (77.2) 71 (51.8) 66 (48.2) 2
NA 33
ALP At diagnosis 109 (53.2) 96 (46.8) 5
ALP at 1st metastasis3
Elevation 33 (53.2) 22 (73.3) 8 (26.7) 3 0.086
Normal 29(46.8) 15 (51.7) 14 (48.3) 0
NA 8
ALP, Alkaline Phosphatase; NA, Not Available; DOD, Died of Disease; CDF, Continuously Disease Free; NED, No Evidence of Disease; AWD, Alive with 
Metastatic Disease; DOC, Died of Other Cause; R0, Negative Resection Margin; R1, Microscopically Positive Resection Margin; R2, Macroscopically 
Positive Resection Margin.
1Mean(minimum- maximum).
2Calculated using Fisher`s exact test.
363 pulmonary metastasis and 7 local recurs.
Table 1. (Continued).
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The ability to reflect tumor burden is another important 
clinical characteristic of a tumor marker. Tumors larger 
than 8 cm showed a higher prevalence of elevated ALP 
at presentation than tumors smaller than 8 cm (62.2% 
vs. 32.3%, P = 0.000) (Table 1). The initial tumor volumes 
on MRI were measured using an ellipsoid formula as 
previously described [19, 20]. Total tumor volume and 
bone tumor volume were directly measured using ellipsoid 
formula and extended soft tissue tumor volume was indi-
rectly calculated by subtracting bone tumor volume from 
total tumor volume. In Spearman correlation analysis, initial 
ALP level was linearly correlated with total tumor volume 
(P = 0.016 in patients ≥15 years) and bone tumor volume 
(P = 0.012 in patients ≥15 years), but not with extended 
soft tissue tumor volume (P = 0.099 in patients ≥15 years), 
suggesting serum ALP reflect bone tumor volume (Table 4).
Diagnostic performance of ALP at diagnosis 
and first metastasis
A tumor marker should be sufficiently sensitive and spe-
cific to exclude other malignant or benign diseases. To 
validate diagnostic performance of elevated ALP, the ALP 
levels at diagnosis of 899 other primary bone lesions were 
Figure 1. Survival analysis of patients with elevated alkaline phosphatase (ALP) at diagnosis and patients with normal ALP. (A) Kaplan–Meier analysis 
for overall survival (OS), including patients who were continuously disease free (CDF) for more than 5 years after surgery, with no evidence of disease 
(NED) for more than 5 years after last metastasectomy, and those who died of disease (DOD). The patients with elevated ALP level at presentation 
showed inferior OS (Log Rank P < 0.001) compared with patients with normal ALP. (B) Kaplan–Meier analysis for disease- free survival (DFS), which 
was analyzed for the patients with localized disease at presentation. The patients with elevated ALP level at presentation showed inferior DFS (Log 
Rank P = 0.005) compared with patients with normal ALP.
Table 2. Univariate and multivariate cox`s regression for prognostic factors.
Overall survival (n = 183) Disease- free survival (n = 168)
Univariate Multivariate Univariate Multivariate
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Metastasis at 
diagnosis
5.60 (3.27 to 9.61) 0.000 3.72 (1.89 to 7.30) 0.000
Age 1.02 (1.00 to 1.04) 0.021 1.02 (1.00 to 1.04) 0.072 1.01 (0.99 to 1.03) 0.254 – –
Size 1.63 (0.91 to 2.92) 0.101 – – 1.66 (0.91 to 3.03) 0.101 – –
Location 4.11 (2.40 to 7.03) 0.000 2.74 (1.27 to 5.90) 0.010 3.12 (1.58 to 6.18) 0.001 1.79 (0.73 to 4.44) 0.206
Histologic 
grade
8.05 (1.12 to 58.05) 0.038 6.15 (0.81 to 46.98) 0.080 3.60 (0.88 to 14.74) 0.075 – –
Huvos grade 1.22 (0.67 to 2.22) 0.517 – – 2.13 (1.23 to 3.71) 0.007 1.90 (1.07 to 3.37) 0.028
Resection 
margin
4.94 (2.60 to 9.40) 0.000 1.472 (0.61 to 3.55) 0.388 3.60 (1.70 to 7.62) 0.001 2.19 (0.82 to 5.81) 0.117
ALP 3.58 (1.98 to 6.48) 0.000 2.12 (1.07 to 4.21) 0.032 2.11 (1.23 to 3.62) 0.006 1.60 (0.88 to 2.93) 0.126
HR, Hazard Ratio; CI, Confidence Interval; ALP, Alkaline Phosphatase.
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examined. Basic demographics of the 899 other primary 
bone lesions and their association with ALP elevation are 
listed in Table 5. The 899 lesions consisted of 208 malig-
nant tumors, 565 benign tumors, and 126 cases of osteo-
myelitis, of which all were pathologically confirmed. 
(Table 6). Accuracy, sensitivity, and specificity of ALP 
among all primary bone lesions were 83.2% (95% CI: 
0.811–0.853), 53.2% (95% CI: 0.475–0.586), and 90.1% 
(95% CI: 0.888–0.913), respectively. Although the sensitiv-
ity of ALP was not excellent, ALP was proven to be 
highly specific on diagnosis of osteosarcoma. Specificity 
of serum ALP for malignant tumors (88.9%) was similar 
to that for benign tumors (90.4%). The prevalence of 
ALP elevation at presentation was the highest for Ewing’s 
sarcoma (26.1%) among malignant tumors and ossifying 
fibroma (21.4%) among benign tumors. Ewing`s sarcoma, 
undifferentiated pleomorphic sarcoma, giant cell tumor 
(GCT), fibrous dysplasia, Langerhans cell histiocytosis 
(LCH), and osteomyelitis may be often confused with 
osteosarcoma in imaging studies. In exclusive analysis with 
these tumor types, the accuracy, sensitivity, and specificity 
of ALP were 76.1% (95% CI: 0.726–0.792), 53.2% (95% 
CI: 0.483–0.575), and 89.2% (95% CI: 0.864–0.916), respec-
tively. This high specificity of ALP may help to discriminate 
osteosarcoma and other tumor types.
The performance of ALP elevation on first metastasis 
was also validated in both the early postoperative phase 
that is prone to metastasis and late stable postoperative 
phase (Table 7). Among 70 patients with metastasis, 62 
had records for serum ALP on first metastasis, of which 
57 were presented as pulmonary metastasis without local 
recur and five as local recurrence. Because the mean latency 
to first metastasis in this study cohort was 
15.1 ± 13.2 months, we analyzed ALP level at approxi-
mately 15 months postoperative and also at approximately 
3 years postoperative to monitor the stable phase. The 
mean follow- up periods for ALP were 14.0 ± 4.0 months 
for 15 months postoperative and 35.1 ± 4.8 months for 
3 years postoperative. The sensitivity of ALP upon metas-
tasis was 53.2% (95% CI: 0.431–0.624), similar to that 
on diagnosis. In early phase, the specificity of serum ALP 
for metastasis declined to 78.2% (95% CI: 0.720–0.839). 
On the other hand, specificity of serum ALP for metastasis 
increased to 90.0% (95% CI: 0.824–0.952) in late stable 
phase. On the basis of these findings, ALP should be 
considered as a supportive method for monitoring metas-
tasis in addition to regular imaging at short intervals 
during the early phase. However, ALP may be an efficient 
means of monitoring during the longer intervals between 
imaging in the late stable phase.
Table 3. Linear mixed model analysis for serum levels of ALP during treatment1.
≥15 years old <15 years old
Elevation (n = 52) Normal (n = 32) Elevation (n = 24) Normal (n = 30)
E ± SE (95% CI) P E ± SE (95% CI) P E ± SE (95% CI) P E ± SE (95% CI) P
Intercept 251.42 ± 30.85 
(190.54–312.30)
0.000 82.89 ± 5.28 
(72.41–93.37)
0.000 486.62 ± 65.42 
(356.34–616.90)
0.000 191.31 ± 19.38 
(152.83–229.80)
0.000
Treatment −45.46 ± 11.30 
(−67.80 to−23.11)
0.000 −1.67 ± 1.82 
(−5.29 to 1.96)
0.364 −107.26 ± 24.65 
(−156.61 to −57.92)
0.000 −15.51 ± 7.08 
(−29.62 to −1.40)
0.032
Survival 104.15 ± 42.35 
(20.58–187.72)
0.015 18.52 ± 13.46 
(−8.18 to 45.23)
0.172 451.47 ± 143.80 
(165.12–737.83)
0.002 58.83 ± 43.08 
(−26.70 to 144.35)
0.175
Treatment * 
survival
−32.30 ± 15.72 
(−63.39 to −1.21)
0.042 −8.96 ± 4.76 
(−18.43 to 0.51)
0.063 −114.92 ± 53.47 
(−221.98 to −7.85)
0.036 −24.34 ± 15.82 
(−55.83 to 7.15)
0.128
E, Estimate; SE, Standard Error; CI, Confidence Interval; ALP, Alkaline Phosphatase.
1Analyzed by fixed model.
Table 4. Spearman correlation analysis between ALP and tumor size
Total tumor volume Bone tumor volume Extended soft tissue tumor volume
Pearson correlation P Pearson correlation P Pearson correlation P
ALP
≥15 years 
(n = 58)
0.316 0.016 0.326 0.012 0.219 0.099
<15 years 
(n = 42)
−0.047 0.766 - 0.079 0.621 −0.038 0.812
ALP, Alkaline Phosphatase.
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Discussion
The prevalence of serum ALP elevation at diagnosis of 
osteosarcoma in our cohort was 53.2% (Table 1). The 
prevalence of ALP elevation at diagnosis varied significantly 
based on sex (P < 0.001), metastasis at presentation 
(P < 0.001), histologic grade (P < 0.001), size (P < 0.001), 
and operability (P = 0.019). All these factors were inde-
pendently associated in multivariate logistic regression 
analysis (data not shown). Unlike other tumor- related 
factors, sex was the only trait that affected ALP level in 
osteosarcoma patients. Male gender was significantly 
associated with higher prevalence of ALP elevation in our 
cohort, but did not lead to an association with survival 
(P = 0.054) and metastasis (P = 0.076). Several large- 
scaled studies reported disaccording results for associations 
between sex and prevalence of ALP elevation at presenta-
tion. Han et al., reported that there was no association 
between sex and prevalence of ALP elevation in their 
cohort of 177 osteosarcoma patients in southern China 
[21]. Rizzoli group reported two contrary results between 
741 osteosarcoma patients enrolled from March 1972 to 
December 1989[4] and 560 osteosarcoma patients enrolled 
Table 5. Basic demographics and prevalence of ALP Elevation at diagnosis of 899 primary bone lesions.
Sex Age
ALP at diagnosis M (%) F (%) P Mean ± SD Min- Max
Malignancy
CS Elevation 5 (8.8) 2 (4.5) 0.465 45.4 ± 16.0 14–91
Normal 52 (91.2) 42 (95.5)
ES Elevation 4 (33.3) 2 (18.2) 0.640 15.4 ± 8.6 1–38
Normal 8 (66.7) 9 (81.8)
UPS Elevation 2 (20.0) 1 (11.1) 1.000 45.2 ± 19.1 16–71
Normal 8 (80.0) 8 (88.9)
CD Elevation 2 (22.2) 1 (10.0) 0.582 48.4 ± 23.8 3–76
Normal 7 (77.8) 9 (90.0)
MM Elevation 4 (15.4) 0 (0.0) 0.069 58.4 ± 10.8 34–84
Normal 22 (84.6) 20 (100.0)
Benign
OC Elevation 18 (15.9) 2 (3.4) 0.022 18.0 ± 11.5 1–63
Normal 95 (84.1) 56 (96.6)
EC Elevation 4 (12.5) 0 (0.0) 0.009 35.6 ± 16.7 5–74
Normal 28 (87.5) 69 (100.0)
GCT Elevation 4 (7.1) 3 (4.8) 0.705 32.6 ± 16.7 5–74
Normal 52 (92.9) 60 (95.2)
FD Elevation 2 (6.7) 4 (16.0) 0.394 26.7 ± 14.4 2–63
Normal 28 (93.3) 21 (84.0)
SBC Elevation 1 (6.3) 0 (0.0) 1.000 23.1 ± 15.5 5–66
Normal 15 (93.8) 7 (100.0)
ABC Elevation 2 (40.0) 0 (0.0) 0.111 16.1 ± 10.6 5–48
Normal 3 (60.0) 9 (100.0)
OF Elevation 3 (50.0) 0 (0.0) 0.055 10.9 ± 7.4 1–22
Normal 3 (50.0) 8 (100.0)
NOF Elevation 1 (25.0) 0 (0.0) 1.000 13.9 ± 4.1 5–17
Normal 3 (75.0) 3 (100.0)
CB Elevation 5 (26.3) 0 (0.0) 0.278 20.6 ± 9.5 5–47
Normal 14 (73.7) 7 (100.0)
OO Elevation 0 (0.0) 0 (0.0) ND 18.5 ± 10.6 3–46
Normal 14 (100.0) 2 (100.0)
LCH Elevation 0 (0.0) 1 (11.1) 0.474 9.0 ± 9.3 1–32
Normal 10 (100.0) 8 (88.9)
OM Elevation 13 (16.3) 3 (6.5) 0.165 37.3 ± 22.4 1–85
Normal 67 (83.8) 43 (93.5)
ALP, Alkaline Phosphatase; OS, Osteosarcoma; CS, Chondrosarcoma; EW, Ewing`s sarcoma; PS, Undifferentiated Pleomorphic Sarcoma (Malignant 
Fibrous Histiocytoma); CD, Chordoma; MM, Multiple Myeloma/Plasmacytoma; ST, Subtotal; OC, Osteochondroma; EC, Enchondroma; GCT, Giant 
Cell Tumor; FD, Fibrous Dysplasia; SBC, Simple Bone Cyst; ABC, Aneurysmal Bone Cyst; OF, Ossifying Fibroma; NOF, Nonossifying fibroma; CB, 
Chondroblastoma; OO, Osteoid Osteoma; LCH, Langerhans Cell Histiocytosis; OM, Osteomyelitis.
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from March 1983 to June 1955[22]. No association was 
found between sex and prevalence of ALP elevation in 
the former cohort, although male gender was significantly 
associated in the latter. However, sex was not associated 
with oncologic outcomes in both cohorts.
The prevalence of elevated ALP at presentation has been 
reported to range from 31.5% to 66.3% [4, 23–27]. The 
main difference among the results seemed to be caused 
by the distribution of metastatic stages in each study 
cohort. Indeed, the prevalence of ALP elevation at diag-
nosis in the metastatic stage was extremely high: 90.5% 
in this study (Table 1) and 91.5% in a previous report 
[4]. Studies that excluded metastatic stage showed a lower 
prevalence (37.2%[25] and 47.0%[26]) than studies that 
included metastatic stage (51.2%[23], 58.5%[27], and 
66.3%[4]). Given these findings, the sensitivity of ALP 
on diagnosis in our cohort (53.2%) may be 
generalizable.
Basic demographic factors of 899 patients with primary 
bone lesion, as well as their association with the prevalence 
of elevated ALP, are listed in Table 5. Higher prevalence 
of ALP elevation at presentation in male was observed 
in most tumors; however, significant association was found 
only in osteochondroma and enchondroma. Mean onset 
ages of most benign tumors and Ewing`s sarcoma were 
under 20 years, whereas those of other malignant tumors 
were over 40 years. All 899 patients received medical 
examination for anesthesia and operability. In respect to 
underlying diseases in 91 patients with elevated ALP, 
pulmonary tuberculosis was most common in seven 
patients, hypertension in three, diabetes and hypothyroid-
ism in two, epilepsy and COPD in one. A total of ten 
patients showed elevated levels of either serum aspartate 
aminotransferase or alanine aminotransferase. Only one 
of them showed accompanied elevation in total serum 
bilirubin level, suggesting hepatobiliary disease that can 
affect serum ALP level, and three were proven as viral 
hepatitis.
The specificity of ALP on diagnosis of osteosarcoma 
has not been previously reported. In comparisons with 
899 other primary bone lesions, ALP showed excellent 
specificity of 90.1% in this study; 88.9% among malignant 
lesions and 90.4% among benign lesions (Table 5). The 
sensitivity and specificity of ALP on metastasis during 
postoperative surveillance is another important character-
istic of a tumor marker. The sensitivity of ALP on first 
metastasis was 53.2% and the specificity were 78.2% in 
the early metastasis- prone stage and 90.0% in late stable 
stage.
Compared with well- established tumor markers in other 
cancers, ALP in osteosarcoma showed similar sensitivity 
on diagnosis with alpha- fetoprotein in hepatocellular car-
cinoma [28, 29] and carcinoembryonic antigen (CEA) and 
cytokeratin 19 fragment (CYFRA- 21) in lung cancer 
[30–32], for which sensitivity ranged from 39.0% to 68.6%. 
On the other hand, the sensitivity of ALP on diagnosis 
Table 6. Two- way contingency table analysis for performance of ALP on diagnosis.
OS
Nonosteosarcoma
Malignant lesions Benign lesions
TotalCS EW PS CD MM ST OC EC GCT FD SBC ABC OF NOF CB OO LCH OM ST
Elevated ALP n (%) 109 (53.2) 7 (6.9) 6 (26.1) 3 (15.8) 3 (15.8) 4 (8.7) 23 (11.1) 20 (11.7) 4 (4.0) 7 (5.9) 6 (10.9) 1 (4.3) 2 (14.3) 3 (21.4) 1 (14.3) 5 (19.2) 0 (0.0) 1 (5.3) 16 (12.7) 66 (9.6) 89 (9.9)
Normal ALP n (%) 96 (46.8) 94 (93.1) 17 (73.9) 16 (84.2) 16 (84.2) 42 (91.3) 185 (88.9) 151 (88.3) 97 (96.0) 112 (94.1) 49 
(89.1)
22 (95.7) 12 (85.7) 11 (78.6) 6 (85.7) 21 (80.8) 16 (100.0) 18 (94.7) 110 (87.3) 625 (90.4) 810 (90.1)
Total (n) 205 101 23 19 19 46 208 171 101 119 55 23 14 14 7 26 16 19 126 691 899
Accuracy % (95% 
CI)
71.2 (0.67–0.75) 81.9 (0.79–0.84) 83.2 (0.81–0.85)
Sensitivity % 
(95% CI)
53.2 (0.49–0.57) 53.2 (0.48–0.58) 53.2 (0.48–0.59)
Specificity % 
(95% CI)
88.9 (0.85–0.92) 90.4 (0.89–0.92) 90.1 (0.89–0.91)
PPV % (95% CI) 82.6 (0.76–0.88) 62.3 (0.56–0.68) 55.1 (0.49–0.61)
NPV % (95% CI) 65.8 (0.63–0.68) 86.7 (0.85–0.88) 89.4 (0.88–0.91)
PLR (95% CI) 4.81 (3.21–7.41) 5.57 (4.28–7.23) 5.37 (4.24–6.76)
NLR (95% CI) 0.53 (0.47–0.60) 0.52 (0.45–0.59) 0.52 (0.45–0.59)
DOR (95% CI) 9.13 (5.32–15.79) 10.75 (7.28–15.91) 10.33 (7.17–14.91)
ALP, Alkaline Phosphatase; OS, Osteosarcoma; CS, Chondrosarcoma; EW, Ewing`s sarcoma; PS, Undifferentiated Pleomorphic Sarcoma (Malignant 
Fibrous Histiocytoma); CD, Chordoma; MM, Multiple Myeloma/Plasmacytoma; ST, Subtotal; OC, Osteochondroma; EC, Enchondroma; GCT, Giant 
Cell Tumor; FD, Fibrous Dysplasia; SBC, Simple Bone Cyst; ABC, Aneurysmal Bone Cyst; OF, Ossifying Fibroma; NOF, Nonossifying fibroma; CB, 
Chondroblastoma; OO, Osteoid Osteoma; LCH, Langerhans Cell Histiocytosis; OM, Osteomyelitis; CI, Confidence Interval; PPV, Positive Predictive 
Value; NPV, Negative Predictive Value; PLR, Positive Likelihood Ratio; NLR, Negative Likelihood Ratio; DOR, Diagnostic Odds Ratio.
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was inferior to that prostate- specific antigen in prostate 
cancer [33], CA 125 in epithelial ovarian cancer [34–36], 
and CA 19–9 in pancreatic cancer [37–39], for which 
sensitivity ranged from 71.9% to 89.3%, but superior to 
that of CA 19–9 and CEA in colorectal cancer [40], and 
CA 15–3 in breast cancer [41, 42], which show sensitivity 
ranging from 15.4% to 31.7%. The sensitivity and speci-
ficity of ALP on metastasis during postoperative surveil-
lance were similar to those of CA 19–9 (sensitivity: 69.0% 
and specificity: 94.5%) and CEA (sensitivity: 47.1% and 
specificity: 95.7%) in colorectal cancer [40]. Overall, the 
diagnostic performance of ALP on diagnosis and metastasis 
Table 6. Two- way contingency table analysis for performance of ALP on diagnosis.
OS
Nonosteosarcoma
Malignant lesions Benign lesions
TotalCS EW PS CD MM ST OC EC GCT FD SBC ABC OF NOF CB OO LCH OM ST
Elevated ALP n (%) 109 (53.2) 7 (6.9) 6 (26.1) 3 (15.8) 3 (15.8) 4 (8.7) 23 (11.1) 20 (11.7) 4 (4.0) 7 (5.9) 6 (10.9) 1 (4.3) 2 (14.3) 3 (21.4) 1 (14.3) 5 (19.2) 0 (0.0) 1 (5.3) 16 (12.7) 66 (9.6) 89 (9.9)
Normal ALP n (%) 96 (46.8) 94 (93.1) 17 (73.9) 16 (84.2) 16 (84.2) 42 (91.3) 185 (88.9) 151 (88.3) 97 (96.0) 112 (94.1) 49 
(89.1)
22 (95.7) 12 (85.7) 11 (78.6) 6 (85.7) 21 (80.8) 16 (100.0) 18 (94.7) 110 (87.3) 625 (90.4) 810 (90.1)
Total (n) 205 101 23 19 19 46 208 171 101 119 55 23 14 14 7 26 16 19 126 691 899
Accuracy % (95% 
CI)
71.2 (0.67–0.75) 81.9 (0.79–0.84) 83.2 (0.81–0.85)
Sensitivity % 
(95% CI)
53.2 (0.49–0.57) 53.2 (0.48–0.58) 53.2 (0.48–0.59)
Specificity % 
(95% CI)
88.9 (0.85–0.92) 90.4 (0.89–0.92) 90.1 (0.89–0.91)
PPV % (95% CI) 82.6 (0.76–0.88) 62.3 (0.56–0.68) 55.1 (0.49–0.61)
NPV % (95% CI) 65.8 (0.63–0.68) 86.7 (0.85–0.88) 89.4 (0.88–0.91)
PLR (95% CI) 4.81 (3.21–7.41) 5.57 (4.28–7.23) 5.37 (4.24–6.76)
NLR (95% CI) 0.53 (0.47–0.60) 0.52 (0.45–0.59) 0.52 (0.45–0.59)
DOR (95% CI) 9.13 (5.32–15.79) 10.75 (7.28–15.91) 10.33 (7.17–14.91)
Table 7. Two- way contingency table analysis for performance of ALP on metastasis.
15 months postoperative1 3 years postoperative2
Metastasis positive3 Metastasis free Total Metastasis positive3 Metastasis free Total
ALP at Metastasis
Elevation N (%) 33 (53.2) 22 (21.8) 55 (33.7) 33 (53.2) 7 (10.0) 40 (30.3)
Normal N (%) 29 (46.8) 79 (78.2) 108 (66.3) 29 (46.8) 63 (90.0) 92 (69.7)
Total 62 101 163 62 70 132
Accuracy % (95% CI) 68.7 (0.610–0.757) 72.7 (0.646–0.783)
Sensitivity % (95% CI) 53.2 (0.431–0.624) 53.2 (0.446–0.591)
Specificity % (95% CI) 78.2 (0.720–0.839) 90.0 (0.824–0.952)
PPV % (95% CI) 60.0 (0.486–0.704) 82.5 (0.691–0.917)
NPV % (95% CI) 73.1 (0.673–0.784) 68.5 (0.627–0.725)
PLR (95% CI) 2.444 (1.539–3.869) 5.323 (2.529–12.436)
NLR (95% CI) 0.598 (0.448–0.790) 0.520 (0.429–0.673)
DOR (95% CI) 4.086 (1.947–8.634) 10.241 (3.760–28.992)
ALP, Alkaline Phosphatase; CI, Confidence Interval; PPV, Positive Predictive Value; NPV, Negative Predictive Value; PLR, Positive Likelihood Ratio; NLR, 
Negative Likelihood Ratio; DOR, Diagnostic Odds Ratio; SD, Standard Deviation.
Latency to metastasis, months (Mean ± SD): 15.1 ± 13.2.
1ALP follow- up period, months (Mean ± SD): 14.0 ± 4.0.
2ALP follow- up period, months (Mean ± SD): 35.1 ± 4.8.
357 pulmonary metastasis and 5 local recurs.
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in osteosarcoma was found to compare favorably with 
well- known tumor markers in other cancers.
In this study, elevated serum ALP level at presentation 
was poorly associated with both OS and DFS; however, 
results from multivariate analysis of our cohort showed 
that ALP was independently associated with OS except 
for DFS. This may cause doubts regarding prognostic 
performance of ALP for metastasis or recurrence. However, 
according to two recent reports of meta- analyses for ALP 
and its prognosis for osteosarcoma, high serum ALP level 
was significantly associated with both OS and DFS poorly 
[43, 44] The discrepancy between this study and the 
mentioned meta- analyses seems to be due to selection 
bias, which could have been caused by our study cohort 
having an unusually strong association with chemosensi-
tivity and metastasis, rather than with prognostic perfor-
mance of ALP for metastasis or recurrence itself. Therefore, 
we expect ALP to be useful for predicting metastasis or 
recurrence, as well as survival.
Unlike other cancers, there are some unique situations 
regarding the management of osteosarcoma, such that 
in the clinic, high specificity of a tumor marker is more 
useful than high sensitivity. First, osteosarcoma can be 
easily screened by plain X- ray, so there is less need for 
a tumor marker with high sensitivity for tumor screen-
ing. Second, MRI and nuclear medicine imaging provide 
sufficiently sensitive information suggestive of osteosar-
coma. Indeed, in the clinical situation, osteosarcoma is 
more likely to be confused with other primary bone 
lesions than to be missed. In this difficult situation, the 
high specificity of ALP may be very useful. Third, recur-
rence of osteosarcoma is mainly presented as pulmonary 
metastasis rather than local recur, so that chest CT is 
essential for postoperative surveillance. Chest CT is usu-
ally followed at short intervals in early postoperative 
surveillance because most metastasis occurs within 2 years 
postoperative. However, chest CT is followed at long 
intervals in the late postoperative surveillance because 
of the decreased metastasis incidence of metastasis and 
the risk of radiation hazard. The specificity of ALP on 
metastasis recovered by 90.0% at 3 years postoperative 
(Table 6), such that ALP elevation during the long inter-
vals between chest CT in late postoperative surveillance 
is strongly suggestive of development of metastasis. ALP 
may therefore be useful to bridge the gap between chest 
CT scans.
ALP has been proven to be a prognostic factor in 
osteosarcoma. However, it is not clear whether the increased 
production of ALP in osteosarcoma is the result of osteo-
blastic tumor cells or reactive bone formation in response 
to osteolysis by the tumor. This study did not provide 
direct evidence for either possibility, but indirect evidences 
favoring production of ALP by tumor cells. First, the 
osteoblastic type showed prominent prevalence of ALP 
elevation at diagnosis compared with other histological 
types (Table 1). Second, ALP was also elevated on pul-
monary metastasis without local recur (49.1%) with a 
similar prevalence to that at diagnosis (53.1%). Third, 
initial ALP level correlated with tumor burden and stage. 
Forth, in primary benign osteolytic tumors such as giant 
cell tumor (GCT), simple bone cyst (SBC), aneurysmal 
bone cyst (ABC), nonossifying fibroma (NOF), and 
Langerhans cell histiocytosis, in which osteogenesis by the 
tumors is seldom observed in pathology, the prevalence 
of ALP elevation at diagnosis was only 7.1%, which may 
be considered the result of reactive bone formation 
(Table 6).
Our study had some limitations. First, it was a retro-
spective study over a long time span. Second, in validating 
the diagnostic performance of ALP, primary bone lesions 
other than osteosarcoma were biased toward certain lesions. 
Malignant tumors weighed heavily in favor of chondro-
sarcoma according to incidence and benign lesions weighed 
in favor of osteochondroma, enchondroma, GCT, and 
osteomyelitis according to the stage. In fact, although SBC, 
ABC, and NOF were common, the number of pathologi-
cally confirmed cases was very small because most were 
in an inactive stage. Third, ALP levels were estimated as 
total enzyme rather than bone isoenzyme, which is theo-
retically specific to bone. However, the bone isoenzyme 
predominates in childhood. In adults the bone and liver 
isoenzymes are present in an equal amount with the 
intestinal isoenzyme accounting for <10%, and the bone 
isoenzyme may be also increased in adults with liver dis-
ease because it is cleared by the liver. For this reason, it 
is not clear whether bone isoenzyme is really superior to 
total enzyme for representing bone formation activity in 
the clinical setting [10, 45]. New candidate tumor markers 
continue to be reported; however, only a small number 
of these have been successfully integrated into clinical 
practice because most lack evidence for clinical value. 
Clinical value of a marker should be validated on the 
basis of sensitivity, specificity, correlation with tumor 
burden, and responsiveness to therapy. Using these criteria, 
ALP was found to be a valuable tumor marker with high 
specificity in osteosarcoma, and is the first validated tumor 
marker in sarcomas.
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